Jane Street’s Arcturus Therapeutics ARCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-29,200
Closed -$179K 11511
2025
Q4
$179K Buy
29,200
+2,500
+9% +$27K ﹤0.01% 9819
2025
Q3
$492K Buy
26,700
+15,200
+132% +$244K ﹤0.01% 7900
2025
Q2
$150K Buy
+11,500
New +$136K ﹤0.01% 8750
2024
Q1
Sell
-23,800
Closed -$750K 9135
2023
Q4
$750K Sell
23,800
-20,300
-46% -$483K ﹤0.01% 6088
2023
Q3
$1.13M Buy
+44,100
New +$1.36M ﹤0.01% 4996
2022
Q4
Sell
-18,800
Closed -$279K 9088
2022
Q3
$279K Buy
+18,800
New +$315K ﹤0.01% 7708
2022
Q2
Sell
-15,300
Closed -$412K 9595
2022
Q1
$412K Sell
15,300
-42,800
-74% -$1.09M ﹤0.01% 7833
2021
Q4
$2.15M Sell
58,100
-7,800
-12% -$318K ﹤0.01% 4344
2021
Q3
$3.15M Buy
65,900
+18,200
+38% +$816K ﹤0.01% 3561
2021
Q2
$1.61M Sell
47,700
-10,700
-18% -$362K ﹤0.01% 4768
2021
Q1
$2.41M Sell
58,400
-74,400
-56% -$4.43M ﹤0.01% 3666
2020
Q4
$5.76M Buy
132,800
+47,100
+55% +$3.19M ﹤0.01% 1963
2020
Q3
$3.68M Buy
85,700
+17,900
+26% +$889K ﹤0.01% 2203
2020
Q2
$3.17M Buy
+67,800
New +$2.34M ﹤0.01% 2433

Other funds holding ARCT

Jane Street's ARCT Position: Q2 2026 in Review

Jane Street reduced its Arcturus Therapeutics (ARCT) stake by 35% in Q2 2026, selling an estimated $63.6K and leaving 15,010 shares worth $101K. The position accounts for ﹤0.01% of the portfolio, ranked #10590.

Jane Street first reported a position in ARCT in Q3 2014 and has held it in 25 quarters since. The position peaked at $6.59M in Q3 2020. 135 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

  • Jane Street held 15,010 shares of Arcturus Therapeutics worth $101K as of Q2 2026.
  • Jane Street sold 8,073 Arcturus Therapeutics shares in Q2 2026, an estimated $63.6K.
  • Arcturus Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #10590 holding.
  • Jane Street first reported a position in Arcturus Therapeutics in Q3 2014 and has held it in 25 quarters since.
  • Jane Street's Arcturus Therapeutics position peaked at $6.59M in Q3 2020.
  • 135 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.